公开(公告)号：US12201616B2

公开(公告)日：2025-01-21

申请号：US17877564

申请日：2022-07-29

Applicant: Opus Genetics, Inc.

Inventor： Mina Sooch ,  Alan R. Meyer ,  Konstantinos Charizanis ,  Bernhard Hoffmann ,  William H. Pitlick

IPC: A61K31/417 ,  A61K9/00 ,  A61K9/08 ,  A61K31/4178 ,  A61K47/12 ,  A61K47/26 ,  A61P27/08 ,  A61P27/10

Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.

公开(公告)号：US12201615B2

公开(公告)日：2025-01-21

申请号：US17877558

申请日：2022-07-29

Applicant: Opus Genetics, Inc.

Inventor： Mina Sooch ,  Alan R. Meyer ,  Konstantinos Charizanis ,  Bernhard Hoffmann ,  William H. Pitlick

IPC: A61K31/417 ,  A61K9/00 ,  A61K9/08 ,  A61K31/4178 ,  A61K47/12 ,  A61K47/26 ,  A61P27/08 ,  A61P27/10

Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.

公开(公告)号：US12161629B2

公开(公告)日：2024-12-10

申请号：US17283038

申请日：2019-10-15

Applicant: Opus Genetics, Inc.

Inventor： William H. Pitlick ,  Alan R. Meyer ,  Mina Sooch ,  Konstantinos Charizanis

IPC: A61K31/417 ,  A61K9/00 ,  A61K31/138 ,  A61K31/222 ,  A61K31/27 ,  A61K31/382 ,  A61K31/4045 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4704 ,  A61K31/472 ,  A61K31/475 ,  A61K31/496 ,  A61K31/498 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5575 ,  A61K31/558 ,  A61K31/683 ,  A61K31/7076 ,  A61K45/06 ,  A61P27/06

Abstract: Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and/or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.